CRISPR Editing in Stem Cells via p53 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Gene editing in human induced pluripotent stem cells (iPSCs) using CRISPR/Cas9 is challenging due to high toxicity and low efficiency, leading to cell death and limited gene targeting rates compared to tumor cell lines, primarily due to sensitivity to DNA damage and apoptosis.
Innovation Solution
Overexpression of anti-apoptotic factors such as dominant negative p53 or Bcl-2 family members, along with the use of chemical inhibitors, to reduce nuclease-mediated toxicity and enhance gene targeting frequencies by inhibiting p53 and Bax pathways, thereby increasing the efficiency of homologous recombination and non-homologous end joining-mediated gene editing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CRISPR/Cas9 nuclease is used to edit human iPSC genomes, then gene editing capability is achieved, but cell toxicity increases and gene targeting efficiency decreases
Solution Approach 1:
The patent introduces an anti-apoptotic factor (such as Bcl-2 or dominant-negative p53) as an intermediary substance that mediates between the CRISPR/Cas9 nuclease and the iPSC cell survival pathway. This intermediary blocks the apoptotic signal triggered by DNA damage, allowing the nuclease to function while preventing cell death, thereby resolving the contradiction between achieving gene editing capability and maintaining high targeting efficiency
Solution Approach 2:
The patent applies preliminary anti-action by pre-treating or co-expressing anti-apoptotic factors before or during CRISPR/Cas9 nuclease delivery. This preliminary protective action counteracts the toxic effects before they can reduce cell viability, enabling sustained gene editing activity and improved overall targeting efficiency without sacrificing cell survival
2Reliability
If CRISPR/Cas9 nuclease is used to edit human iPSC genomes, then gene editing capability is achieved, but cell death rate increases
Solution Approach 1:
The patent converts the harmful apoptotic response to DNA damage into a beneficial outcome by using the p53 pathway itself. By expressing dominant-negative p53 or anti-apoptotic Bcl-2 family members, the system harnesses the cell's own DNA damage response machinery to protect cells rather than kill them, allowing CRISPR/Cas9 editing to proceed with minimal cell death while maintaining editing capability
Solution Approach 2:
The anti-apoptotic factor serves as a protective intermediary that blocks the lethal signaling pathway between DNA double-strand breaks and apoptosis execution. This intermediary substance allows the nuclease-induced DNA damage to be tolerated and repaired rather than triggering cell death, thus resolving the contradiction between achieving gene editing and preventing cell death
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases gene targeting frequencies in human iPSCs, allowing for efficient multiplex gene replacements and base pair changes, reducing the need for antibiotic selection and maintaining pluripotency, thus improving both experimental and therapeutic applications of genetically modified stem cells.
Implementation Method 1
the Cas9 protein generates two nicks in the target DNA, creating a blunt double-strand break (DSB)
Implementation Method 2
Watson-Crick base-pairing between the sgRNA and target DNA proceeds in a ratchet mechanism to form an R-loop
Implementation Method 3
repaired by the non-homologous end joining (NHEJ) pathway or template-directed homologous recombination (HR)
Data Source
AI summary
Inhibiting p53 or Bax can be used to improve nuclease-mediated gene targeting frequencies in stem cells. This inhibition can be achieved, e.g., by overexpression of anti-apoptosis proteins or by silencing or reducing p53 or Bax expression. This technique can be used in conjunction with other rapidly developing CRISPR technologies, including improvements in specificity, other types of nucleases, and further enrichment, screening, and selection schemes, to expand the use of stem cells in experimental studies and tissue engineering for therapeutic purposes.